Literature DB >> 24487413

Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients.

R Kihara1, Y Nagata2, H Kiyoi1, T Kato1, E Yamamoto1, K Suzuki1, F Chen1, N Asou3, S Ohtake4, S Miyawaki5, Y Miyazaki6, T Sakura7, Y Ozawa8, N Usui9, H Kanamori10, T Kiguchi11, K Imai12, N Uike13, F Kimura14, K Kitamura15, C Nakaseko16, M Onizuka17, A Takeshita18, F Ishida19, H Suzushima20, Y Kato21, H Miwa22, Y Shiraishi23, K Chiba23, H Tanaka24, S Miyano25, S Ogawa2, T Naoe26.   

Abstract

To clarify the cooperative roles of recurrently identified mutations and to establish a more precise risk classification system in acute myeloid leukemia (AML), we comprehensively analyzed mutations in 51 genes, as well as cytogenetics and 11 chimeric transcripts, in 197 adult patients with de novo AML who were registered in the Japan Adult Leukemia Study Group AML201 study. We identified a total of 505 mutations in 44 genes, while only five genes, FLT3, NPM1, CEBPA, DNMT3A and KIT, were mutated in more than 10% of the patients. Although several cooperative and exclusive mutation patterns were observed, the accumulated mutation number was higher in cytogenetically normal AML and lower in AML with RUNX1-RUNX1T1 and CBFB-MYH11, indicating a strong potential of these translocations for the initiation of AML. Furthermore, we evaluated the prognostic impacts of each sole mutation and the combinations of mutations and/or cytogenetics, and demonstrated that AML patients could be clearly stratified into five risk groups for overall survival by including the mutation status of DNMT3A, MLL-PTD and TP53 genes in the risk classification system of the European LeukemiaNet. These results indicate that the prognosis of AML could be stratified by the major mutation status in combination with cytogenetics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24487413     DOI: 10.1038/leu.2014.55

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  44 in total

1.  Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype.

Authors:  Vera Grossmann; Enrico Tiacci; Antony B Holmes; Alexander Kohlmann; Maria Paola Martelli; Wolfgang Kern; Ariele Spanhol-Rosseto; Hans-Ulrich Klein; Martin Dugas; Sonja Schindela; Vladimir Trifonov; Susanne Schnittger; Claudia Haferlach; Renato Bassan; Victoria A Wells; Orietta Spinelli; Joseph Chan; Roberta Rossi; Stefano Baldoni; Luca De Carolis; Katharina Goetze; Hubert Serve; Rudolf Peceny; Karl-Anton Kreuzer; Daniel Oruzio; Giorgina Specchia; Francesco Di Raimondo; Francesco Fabbiano; Marco Sborgia; Arcangelo Liso; Laurent Farinelli; Alessandro Rambaldi; Laura Pasqualucci; Raul Rabadan; Torsten Haferlach; Brunangelo Falini
Journal:  Blood       Date:  2011-10-19       Impact factor: 22.113

Review 2.  The role of mutations in epigenetic regulators in myeloid malignancies.

Authors:  Alan H Shih; Omar Abdel-Wahab; Jay P Patel; Ross L Levine
Journal:  Nat Rev Cancer       Date:  2012-08-17       Impact factor: 60.716

3.  Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study.

Authors:  Shigeki Ohtake; Shuichi Miyawaki; Hiroyuki Fujita; Hitoshi Kiyoi; Katsuji Shinagawa; Noriko Usui; Hirokazu Okumura; Koichi Miyamura; Chiaki Nakaseko; Yasushi Miyazaki; Atsushi Fujieda; Tadashi Nagai; Takahisa Yamane; Masafumi Taniwaki; Masatomo Takahashi; Fumiharu Yagasaki; Yukihiko Kimura; Norio Asou; Hisashi Sakamaki; Hiroshi Handa; Sumihisa Honda; Kazunori Ohnishi; Tomoki Naoe; Ryuzo Ohno
Journal:  Blood       Date:  2010-08-06       Impact factor: 22.113

Review 4.  Acute myeloid leukaemia.

Authors:  Elihu Estey; Hartmut Döhner
Journal:  Lancet       Date:  2006-11-25       Impact factor: 79.321

5.  DNMT3A mutations in acute myeloid leukemia.

Authors:  Timothy J Ley; Li Ding; Matthew J Walter; Michael D McLellan; Tamara Lamprecht; David E Larson; Cyriac Kandoth; Jacqueline E Payton; Jack Baty; John Welch; Christopher C Harris; Cheryl F Lichti; R Reid Townsend; Robert S Fulton; David J Dooling; Daniel C Koboldt; Heather Schmidt; Qunyuan Zhang; John R Osborne; Ling Lin; Michelle O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Vincent J Magrini; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Joshua J Conyers; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd Wylie; Jason Walker; Joelle Kalicki; Mark A Watson; Sharon Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Peter Westervelt; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Richard K Wilson
Journal:  N Engl J Med       Date:  2010-11-10       Impact factor: 91.245

Review 6.  Genetic profiling in acute myeloid leukaemia--where are we and what is its role in patient management.

Authors:  Yishai Ofran; Jacob M Rowe
Journal:  Br J Haematol       Date:  2012-12-13       Impact factor: 6.998

Review 7.  Gene mutations of acute myeloid leukemia in the genome era.

Authors:  Tomoki Naoe; Hitoshi Kiyoi
Journal:  Int J Hematol       Date:  2013-01-29       Impact factor: 2.490

8.  Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.

Authors:  Krzysztof Mrózek; Guido Marcucci; Deedra Nicolet; Kati S Maharry; Heiko Becker; Susan P Whitman; Klaus H Metzeler; Sebastian Schwind; Yue-Zhong Wu; Jessica Kohlschmidt; Mark J Pettenati; Nyla A Heerema; AnneMarie W Block; Shivanand R Patil; Maria R Baer; Jonathan E Kolitz; Joseph O Moore; Andrew J Carroll; Richard M Stone; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2012-09-17       Impact factor: 44.544

9.  Acquired mutations in TET2 are common in myelodysplastic syndromes.

Authors:  Saskia M C Langemeijer; Roland P Kuiper; Marieke Berends; Ruth Knops; Mariam G Aslanyan; Marion Massop; Ellen Stevens-Linders; Patricia van Hoogen; Ad Geurts van Kessel; Reinier A P Raymakers; Eveline J Kamping; Gregor E Verhoef; Estelle Verburgh; Anne Hagemeijer; Peter Vandenberghe; Theo de Witte; Bert A van der Reijden; Joop H Jansen
Journal:  Nat Genet       Date:  2009-05-31       Impact factor: 38.330

10.  IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Authors:  Peter Paschka; Richard F Schlenk; Verena I Gaidzik; Marianne Habdank; Jan Krönke; Lars Bullinger; Daniela Späth; Sabine Kayser; Manuela Zucknick; Katharina Götze; Heinz-A Horst; Ulrich Germing; Hartmut Döhner; Konstanze Döhner
Journal:  J Clin Oncol       Date:  2010-06-21       Impact factor: 50.717

View more
  78 in total

1.  Autologous hematopoietic cell transplantation for acute myeloid leukemia in adults: 25 years of experience in Japan.

Authors:  Masamitsu Yanada; Akiyoshi Takami; Shohei Mizuno; Jinichi Mori; Takaaki Chou; Kensuke Usuki; Hitoji Uchiyama; Itsuto Amano; Shiro Fujii; Toshihiro Miyamoto; Takeshi Saito; Tomohiko Kamimura; Tatsuo Ichinohe; Takahiro Fukuda; Shinichiro Okamoto; Yoshiko Atsuta; Shingo Yano
Journal:  Int J Hematol       Date:  2019-10-14       Impact factor: 2.490

2.  Genetic alterations and their clinical implications in older patients with acute myeloid leukemia.

Authors:  C-H Tsai; H-A Hou; J-L Tang; C-Y Liu; C-C Lin; W-C Chou; M-H Tseng; Y-C Chiang; Y-Y Kuo; M-C Liu; C-W Liu; L-I Lin; W Tsay; M Yao; C-C Li; S-Y Huang; B-S Ko; S-C Hsu; C-Y Chen; C-T Lin; S-J Wu; H-F Tien
Journal:  Leukemia       Date:  2016-03-17       Impact factor: 11.528

Review 3.  Role of RUNX1 in hematological malignancies.

Authors:  Raman Sood; Yasuhiko Kamikubo; Paul Liu
Journal:  Blood       Date:  2017-02-08       Impact factor: 22.113

4.  Clinical characteristics and prognosis of acute myeloid leukemia associated with DNA-methylation regulatory gene mutations.

Authors:  Takeshi Ryotokuji; Hiroki Yamaguchi; Toshimitsu Ueki; Kensuke Usuki; Saiko Kurosawa; Yutaka Kobayashi; Eri Kawata; Kenji Tajika; Seiji Gomi; Junya Kanda; Anna Kobayashi; Ikuko Omori; Atsushi Marumo; Yusuke Fujiwara; Shunsuke Yui; Kazuki Terada; Keiko Fukunaga; Tsuneaki Hirakawa; Kunihito Arai; Tomoaki Kitano; Fumiko Kosaka; Hayato Tamai; Kazutaka Nakayama; Satoshi Wakita; Takahiro Fukuda; Koiti Inokuchi
Journal:  Haematologica       Date:  2016-05-31       Impact factor: 9.941

5.  Clinical Evaluation of a Novel Nine-Gene Panel for Ion Torrent PGM Sequencing of Myeloid Malignancies.

Authors:  Milena Ivanova; Velizar Shivarov; Ivan Pavlov; Konstantinos Lilakos; Elissaveta Naumova
Journal:  Mol Diagn Ther       Date:  2016-02       Impact factor: 4.074

6.  Complex molecular genetic abnormalities involving three or more genetic mutations are important prognostic factors for acute myeloid leukemia.

Authors:  S Wakita; H Yamaguchi; T Ueki; K Usuki; S Kurosawa; Y Kobayashi; E Kawata; K Tajika; S Gomi; M Koizumi; Y Fujiwara; S Yui; K Fukunaga; T Ryotokuji; T Hirakawa; K Arai; T Kitano; F Kosaka; H Tamai; K Nakayama; T Fukuda; K Inokuchi
Journal:  Leukemia       Date:  2015-10-21       Impact factor: 11.528

7.  Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis.

Authors:  Elodie Pronier; Robert L Bowman; Jihae Ahn; Jacob Glass; Cyriac Kandoth; Tiffany R Merlinsky; Justin T Whitfield; Benjamin H Durham; Antoine Gruet; Amritha Varshini Hanasoge Somasundara; Raajit Rampal; Ari Melnick; Richard P Koche; Barry S Taylor; Ross L Levine
Journal:  Blood       Date:  2018-07-31       Impact factor: 22.113

8.  Somatic PHF6 mutations in 1760 cases with various myeloid neoplasms.

Authors:  T Mori; Y Nagata; H Makishima; M Sanada; Y Shiozawa; A Kon; T Yoshizato; A Sato-Otsubo; K Kataoka; Y Shiraishi; K Chiba; H Tanaka; K Ishiyama; S Miyawaki; H Mori; T Nakamaki; R Kihara; H Kiyoi; H P Koeffler; L-Y Shih; S Miyano; T Naoe; C Haferlach; W Kern; T Haferlach; S Ogawa; K Yoshida
Journal:  Leukemia       Date:  2016-08-01       Impact factor: 11.528

9.  Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.

Authors:  Mohammed Gbadamosi; Soheil Meshinchi; Jatinder K Lamba
Journal:  Future Oncol       Date:  2018-07-24       Impact factor: 3.404

10.  Parallel targeted next generation sequencing of childhood and adult acute myeloid leukemia patients reveals uniform genomic profile of the disease.

Authors:  Irena Marjanovic; Jelena Kostic; Bojana Stanic; Nadja Pejanovic; Bojana Lucic; Teodora Karan-Djurasevic; Dragana Janic; Lidija Dokmanovic; Srdja Jankovic; Nada Suvajdzic Vukovic; Dragica Tomin; Ognjen Perisic; Goran Rakocevic; Milos Popovic; Sonja Pavlovic; Natasa Tosic
Journal:  Tumour Biol       Date:  2016-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.